CoChat

Effect of adding sitagliptin, a dipeptidyl peptidase‐4 inhibitor, to metformin on 24‐h glycaemic control and β‐cell function in patients with type 2 diabetes

Brazg, R., Xu, L., Dalla Man, C., Cobelli, C., Thomas, K., Stein, P. P. · 2007 · Diabetes, Obesity and Metabolism
Cited by 138

The DOI matches its Crossref record.

Abstract

Aim: The aim of this study was to assess the effect of sitagliptin, a dipeptidyl peptidase‐4 inhibitor, on 24‐h glucose control when added to the regimen of patients with type 2 diabetes who had inadequate glycaemic control on metformin therapy. Methods: In a double‐blind, randomized, placebo‐controlled, two‐period crossover study, patients with type 2 diabetes with inadequate glycaemic control on metformin monotherapy (i.e. on a stable dose of ≥1500 mg/day for ≥6 weeks prior to the screening visit and an haemoglobin A 1c (HbA 1c ) ≥6.5% and <10% and fasting plasma glucose (FPG) ≤240 mg/dl) were recruited for participation. A total of 28 patients (baseline HbA 1c range = 6.5–9.6%) receiving metformin were randomized into one of two treatment sequences: the addition of placebo for 4 weeks followed by the addition of sitagliptin 50 mg twice daily (b.i.d.) for 4 weeks, or vice versa. At the end of each treatment period, patients were domiciled for frequent blood sampling over 24 h. The primary endpoint was 24‐h weighted mean glucose (WMG) and secondary endpoints included change in FPG, mean of 7 daily self‐blood glucose measurements (MDG) and fructosamine. β‐cell function was assessed from glucose and C‐peptide concentrations were measured during the 5‐h period after a standard breakfast meal by using the C‐peptide minimal model. Results: Despite a carryover effect from period 1 to period 2, the combined period 1 and period 2 results for glycaemic endpoints were statistically significant for sitagliptin relative to placebo when added to ongoing metformin therapy. To account for the carryover effect, the period 1 results were also compared between the groups. Following period 1, there were significant least‐squares (LS) mean reductions in 24‐h WMG of 32.8 mg/dl, significant LS mean reduction from baseline in MDG of 28 mg/dl, FPG of 20.3 mg/dl and fructosamine of 33.7 mmol/l in patients treated with sitagliptin relative to placebo (p < 0.05). When added to ongoing metformin therapy, parameters of β‐cell function were significantly improved with sitagliptin compared with placebo. No weight gain or increases in gastrointestinal adverse events or hypoglycaemia events were observed with sitagliptin relative to placebo during this study. Conclusions: In this study, the addition of sitagliptin 50 mg b.i.d. to ongoing metformin therapy improved 24‐h glycaemic control and β‐cell function, and was generally well tolerated in patients with type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2006.00691.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 138

Metadata

Authors
Brazg, R., Xu, L., Dalla Man, C., Cobelli, C., Thomas, K., & Stein, P. P.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2006-12-15
Volume
9
Issue
2
Pages
186-193
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1996407482
Cited by
138
References
0
FWCI
11.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of adding sitagliptin, a dipeptidyl peptidase‐4 inhibitor, to metformin on 24‐h glycaemic control and β‐cell function in patients with type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1463-1326.2006.00691.x
The paper
Brazg, R., Xu, L., Dalla Man, C., Cobelli, C., Thomas, K., & Stein, P. P. (2007). Effect of adding sitagliptin, a dipeptidyl peptidase‐4 inhibitor, to metformin on 24‐h glycaemic control and β‐cell function in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2006.00691.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.